JP2024513522A5 - - Google Patents

Info

Publication number
JP2024513522A5
JP2024513522A5 JP2023562566A JP2023562566A JP2024513522A5 JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5 JP 2023562566 A JP2023562566 A JP 2023562566A JP 2023562566 A JP2023562566 A JP 2023562566A JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
population
combination
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023684 external-priority patent/WO2022216831A1/en
Publication of JP2024513522A publication Critical patent/JP2024513522A/ja
Publication of JP2024513522A5 publication Critical patent/JP2024513522A5/ja
Pending legal-status Critical Current

Links

JP2023562566A 2021-04-08 2022-04-06 Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療 Pending JP2024513522A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172414P 2021-04-08 2021-04-08
US63/172,414 2021-04-08
US202163290359P 2021-12-16 2021-12-16
US63/290,359 2021-12-16
PCT/US2022/023684 WO2022216831A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and a her2 targeted antibody

Publications (2)

Publication Number Publication Date
JP2024513522A JP2024513522A (ja) 2024-03-25
JP2024513522A5 true JP2024513522A5 (cg-RX-API-DMAC10.html) 2025-04-14

Family

ID=83545892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562566A Pending JP2024513522A (ja) 2021-04-08 2022-04-06 Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療

Country Status (6)

Country Link
US (1) US20240197778A1 (cg-RX-API-DMAC10.html)
EP (1) EP4319771A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513522A (cg-RX-API-DMAC10.html)
KR (1) KR20240024048A (cg-RX-API-DMAC10.html)
AU (1) AU2022254689A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022216831A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3002685A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of her2-expressing solid tumors
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
CN107267454B (zh) * 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018014577A (es) * 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018026971A1 (en) 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
WO2019008154A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3- (AZOLYLMETHOXY) BIPHENYL DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
WO2019008152A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3697500A1 (en) 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CN111971059A (zh) 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
CN112839666A (zh) * 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법

Similar Documents

Publication Publication Date Title
JP2024513958A5 (cg-RX-API-DMAC10.html)
Diorio et al. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Shin et al. NK cell-based immunotherapies in cancer
KR102883631B1 (ko) 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법
JP2024515169A5 (cg-RX-API-DMAC10.html)
JP2024513514A5 (cg-RX-API-DMAC10.html)
Pistoia et al. Human γδ T-cells: from surface receptors to the therapy of high-risk leukemias
US6544787B1 (en) Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
JP2024527559A5 (cg-RX-API-DMAC10.html)
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
US12060577B2 (en) Compositions for expanding natural killer cells
ES2224122T3 (es) Inmunoterapia de cancer con linfocitos alogenicos.
Otegbeye et al. A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors
Van Ostaijen-Ten Dam et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
CN115137752A (zh) 用于干细胞移植的方法
JP2022522231A5 (cg-RX-API-DMAC10.html)
PT2613801T (pt) Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma
Bader et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells
EP1648508A1 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
AU2023257377A1 (en) Allogeneic t cells for treatment of hematological malignancies
Gonzalez-Brito et al. The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
JP2022023136A5 (cg-RX-API-DMAC10.html)
US20210353674A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer